Despite its anti-inflammatory and antiatherogenic effects, adiponectin is potentially associated with adverse clinical outcomes, such as all-cause mortality. As plasma adiponectin levels are strongly influenced by single nucleotide polymorphisms in the gene encoding T-cadherin (CDH13), we conducted a longitudinal study to investigate the possible link between the CDH13 genotype, plasma adiponectin levels, and all-cause mortality.
Adiponectin is an adipocyte-derived secretory protein that has peripheral insulin-sensitizing activity (1) . Adiponectin also exerts systemic antiinflammatory effects via suppression of the growth and proliferation of macrophage progenitors, as well as the inflammation caused by fully differentiated macrophages (1) . Further, cross-sectional studies in various populations have reported that a higher plasma adiponectin level is associated with a lower frequency of type 2 diabetes (2), metabolic syndrome (3), and thinner carotid arterial wall thickness (4) . The results of these experimental studies and populationbased cross-sectional association studies indicate that adiponectin is a cardioprotective factor in humans.
In contrast, several longitudinal epidemiological studies have reported that a higher plasma adiponectin level was associated with an increased incidence of cardiovascular disease (CVD) (5, 6) and mortality (7) (8) (9) (10) (11) (12) . The underlying mechanism of the inverse association between these crosssectional association studies and longitudinal prospective studies, the "adiponectin paradox," is unclear and prevents a complete understanding of the biological role of adiponectin. A number of possibilities warrant investigation including reverse causality stemming from a compensatory increase of adiponectin to subclinical CVD risks and adiponectin resistance (13) .
Recent advances in DNA array technology have enabled the highthroughput analysis of single nucleotide polymorphisms (SNPs). Genome-wide association studies (GWAS) have successfully identified SNPs of the CDH13 gene that have a strong association with plasma adiponectin levels (14, 15) . The CDH13 gene encodes T-cadherin, a receptor for hexameric and high-molecular weight forms of adiponectin (HMWA) (16) . Although earlier studies (17, 18) and recent GWAS in European subjects (19, 20) reported a strong susceptibility of SNPs in the ADIPOQ gene that encodes adiponectin, GWAS of adiponectin in East Asian subjects, namely Korean (15) and Japanese (21) , identified SNPs in the CDH13 locus, such as rs4783244.
Because plasma adiponectin levels in subjects homozygous for the allele that with an association with higher adiponectin levels (affected allele) were ;1.5 times higher than those homozygous for the allele without (unaffected allele) (21), genetic variation might be partially involved in the adiponectin paradox.
To clarify our hypothesis, we analyzed the possible interaction of the CDH13 genotype in the association of plasma levels of HMWA and all-cause mortality in Japanese middle-aged to elderly community residents.
RESEARCH DESIGN AND METHODS
This longitudinal study enrolled community-dwelling Japanese subjects living in Nomura Town, Ehime Prefecture, a mostly rural town with 11,000 inhabitants. Study subjects were recruited through a community-based annual medical check-up process in 2002 as part of the Shimanami Health Promoting Program (J-SHIPP) (3, 22, 23) , which was a longitudinal epidemiological study evaluating factors relating to CVD, dementia, and death. Among a total of 2,721 residents who agreed to participate in the J-SHIPP study and completed baseline clinical measurements, 2,020 persons for whom an overnight fasting plasma sample was provided (.11 h) for HMWA measurement (n = 2,084), for whom CDH13 genotype was determined (n = 2,042), and for whom mortality during this study period could be followed up were enrolled in this analysis. All study procedures were approved by the ethics committee of Ehime University Graduate School of Medicine, and all subjects provided signed informed consent prior to participation.
Baseline Measurements
Baseline clinical characteristics evaluated at medical checkups, including anthropometric measurements, blood pressure (BP), and basic plasma markers, were obtained from personal health records. Additional characteristics, including medication and history of CVD, were obtained by individual interviews using a structured questionnaire. 
Measurement of Plasma HMWA Levels
Plasma samples were obtained from each subject after a period of overnight fasting of at least 11 h. Samples were immediately frozen and stored at 2808C until analysis. Plasma concentrations of HMWA were determined using an ELISA assay (Fujirebio, Tokyo, Japan) (3, 24) , which consisted of HMWA-specific capture antibody (IH7) and HMWAspecific horseradish peroxidaseconjugated detection antibody (POD-IH7).
The specificity of this monoclonal antibody has previously been described (25) . Standardized HMWA concentrations were determined by human HMWA purified by gelatincellulofine column chromatography. Intra-and interassay coefficient variations of the adiponectin assay were 4.4% and 9.7%, respectively.
Genotyping DNA was extracted from peripheral blood using a QIAamp DNA blood kit (Qiagen, Hilden, Germany). The SNP rs4783244 in the CDH13 gene was genotyped by a TaqMan probe assay using commercially available primers and probes purchased from the Assayon-Demand system (Life Technologies, Carlsbad, CA). Fluorescence of PCR products was measured using an ABI PRISM 7900HT sequence detector (Life Technologies, Tokyo, Japan).
Statistical Analysis
Differences in the numeric variables of baseline data were assessed by ANOVA, and differences in frequency were assessed by a x 2 test. Overall survival ratio was calculated by Kaplan-Meier analysis. Covariate-adjusted hazard ratio (HR) for total mortality was analyzed by Cox proportional hazards regression analysis. Combined HR was calculated under a random effects model. A P value ,0.05 was considered statistically significant.
RESULTS
Baseline clinical characteristics of study subjects are shown in Table 1 . Mean HMWA level in female subjects (7.62 6 4.56 mg/mL) was nearly double that in male subjects (4.12 6 2.93 mg/mL, P , 0.001). Subjects were therefore divided by HMWA quartile within each sex and then combined to avoid potential sex differences (Table 1) . Table 1 also summarizes the differences in clinical parameters among HMWA quartiles. Age was strongly and positively associated with HMWA quartile, while BMI showed a significant inverse association. Plasma levels of HDL cholesterol, triglyceride, and glucose were also significantly different among HMWA quartiles. In a simple comparison, SBP and eGFR were significantly associated with HMWA quartile; however, these associations disappeared after adjustment for age and BMI.
Mean follow-up duration was 6.5 years, during which time 84 subjects died. Figure 1A shows the Kaplan-Meier plot for all-cause mortality by HMWA quartile, with the highest quartile being strongly associated with all-cause mortality. For clarification of whether the prognostic significance of HMWA was independent of possible covariates, Cox regression analysis was performed by a forward covariate selection method. Table 2 summarizes the HR of the 4th quartile of HMWA, as well as 10 mg/mL increases in HMWA, in relation to total mortality. In any model adjusted for relevant clinical parameters (Table 2 [models 1-3]), higher plasma HMWA levels were independently associated with total mortality.
The G allele of the CDH13 rs4783244 genotype was strongly associated with baseline plasma HMWA level (Fig. 2) . Although obese subjects, defined as having a BMI .25 kg/m 2 , showed significantly lower HMWA levels in both sexes (male obese 3.25 6 2.22, nonobese 4.49 6 3.12, P , 0.001; female 6.37 6 3.68, 8.18 6 4.86, P , 0.001), the association between CDH13 genotype and HMWA was independent of obesity status (Fig. 2) . Per-allele effect size of the genotype calculated by a regression analysis adjusted for age, sex, and BMI was 1.65 mg/mL (P , 0.001).
Nevertheless, the prognostic significance of HMWA on total mortality was independent of the CDH13 genotype (Table 2 [model 4]). In a separate analysis by the genotype, however, HR for all-cause mortality was linearly increased with the number of G alleles (Fig. 1B) , and the association between HMWA and poor prognosis was seen only in the GG genotype carries. The term of interaction between the CHD13 genotype and plasma HMWA level was identified as a significant factor for all-cause mortality (P = 0.023) in the Cox regression analysis adjusted for the same covariates as are adjusted for in model 3 of Table 2 . These results indicate that the poor prognostic significance of HMWA was genotype dependent.
CONCLUSIONS
In this longitudinal study in a general population, we observed that higher plasma HMWA levels were significantly associated with all-cause mortality. Further, the association between HMWA and mortality showed a high degree of variation among CDH13 rs4783244 genotypes. To our knowledge, this is the first study showing a genotype-dependent association of HMWA with all-cause mortality.
Our results confirmed the increased risk of all-cause mortality in subjects with a higher baseline HMWA level. Several previous studies reported a similar relationship in general populations (5, (8) (9) (10) , as well as in patients with type 2 diabetes (7), coronary artery disease (6, 11) , and chronic heart failure (12). Higher plasma HMWA in a general population is a complex phenotype that may represent a clustering of subclinical risk statuses, namely, reduced renal and cardiac function, obesity, insulin resistance and metabolic disorders, atherosclerosis, systemic inflammation, weight loss in elderly, and anemia. However, these studies were conducted mainly in European subjects (7, (9) (10) (11) (12) or in European and African American subjects (5, 6, 8) , with no positive results being reported from East Asian subjects. In contrast, it has been reported that the Japanese population has distinct anthropometric characteristics, including a lower frequency of obesity compared with developed Western countries (26) , and considerably lower plasma adiponectin levels (27) , even in comparison with Japanese Americans living in Hawaii (28) . In populations with lower HMWA levels, our results demonstrate the cross-validity of the prognostic significance of HMWA.
We also found an inverse association between HMWA and all-cause mortality between CDH13 TT and CDH13 GG genotype carriers, with the HR of the CDH13 TT genotype failing to reach statistical significance, presumably due to the smaller subsample size. Although the CDH13 gene is known to encode T-cadherin, a receptor for HMWA, the functionality of each CDH13 rs4783244 genotype or other unidentified responsible SNPs in linkage disequilibrium have not been clarified. However, T-cadherin knockout mice were reported to show dramatically increased plasma adiponectin levels due to impaired linkage between adiponectin and target cells (29) . It is therefore possible that the G allele of the CDH13 genotype causes secondary hyperadiponectinemina by altering the amount or functionality of T-cadherin. This genetically dependent adiponectin resistance and consequent reduction in adiponectin's anti-inflammatory and antiatherogenic effects may explain the increased mortality ratio in subjects with higher HMWA levels. Because differences in HMWA levels for each CDH13 rs4783244 genotype were similar between nonobese and obese subjects (Fig. 2) , the production of adiponectin and formation of highmolecular weight isoforms might not be a factor in the genotype-specific mortality ratio.
According to the HapMap database (http://hapmap.ncbi.nlm.nih.gov/), frequency of the CDH13 rs4783244 genotype is similar across all ethnic groups. However, GWAS in European subjects (19, 20) identified only the ADIPOQ gene as susceptible loci for plasma adiponectin levels. Although more large-scale GWAS might identify the CDH13 gene as another susceptible loci, it is probable that genetic polymorphisms in the ADIPOQ gene have a larger effect than those in the CDH13 genotype in European populations regardless of the type of adiponectin complex (30) . Because the ADIPOQ gene encodes adiponectin, our "genetic adiponectin resistance" hypothesis involving the CDH13 gene as a means of explanation might not be easily extrapolated to other populations. However, our results provide novel supporting evidence that adiponectin resistance is a key mechanism of the adiponectin paradox, which is lacking in other proposed mechanisms such as renal dysfunction and decreased adiponectin clearance, weight loss, or sarcopenia in the elderly and compensatory rise in adiponectin due to subclinical risks (reverse causality) (13) . Our present results also excluded the possibility of confounding effects of decreased renal function.
Several limitations of this study warrant mention. First, we could not evaluate a cause-specific mortality, particularly cardiovascular mortality. Results of long-term analysis for cardiovascular mortality would strengthen our findings. Second, we did not analyze other molecular isoforms of adiponectin. As T-cadherin is a receptor for HMWA and the HMW isoform is considered an active form, further investigations regarding isoform specificity will be necessary. Third, this study contained~2,000 study subjects. Replication studies, particularly in East Asian populations, with a larger sample size are therefore needed to confirm our present findings.
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